SYNACT Aktie

 

The United States Patent and Trademark Office has issued a Notice of Allowance for SynAct Pharma's patent application covering the use of resomelagon in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis. This indicates that the patent office intends to grant the patent, further strengthening the company's patent portfolio. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/04/synact-pharma-secures-patent-for-resomelagon-in-combination-with-mtx/ This is a press release from BioStock - Connecting Innovation &...

An investigator-initiated phase II study has been launched with SynAct Pharma's lead candidate, resomelagon, in patients with dengue in Brazil. This trial runs in parallel with the ongoing study in rheumatoid arthritis. BioStock spoke with the company's CSO, Thomas Jonassen, who sees strong potential for resomelagon in both RA and dengue, as well as other indications: – We work behind the scenes to expand our pipeline and look forward to presenting the next program(s) once we are ready, says Jonassen. Read the full article at biostock.se (https://www.biostock.se/en/): https://www....

SynAct Pharma has been granted a pivotal US patent protecting the crystal form of resomelagon, a drug candidate currently in phase IIb clinical development for rheumatoid arthritis. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/03/synact-pharma-secures-key-us-patent/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se...